Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4276 AL 4290

Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease

Musaeus CS, Shafi MM, Santarnecchi E, Herman ST, Press DZ.

J Alzheimers Dis. 2017;58(4):1065-1076. doi: 10.3233/JAD-160742.

The novel PSEN1 M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family

Gallo M, Frangipane F, Cupidi C, De Bartolo M, Turone S, Ferrari C, Nacmias B, Grimaldi G, Laganà V, Colao R, Bernardi L, Anfossi M, Conidi ME, Vasso F, Curcio SAM, Mirabelli M, Smirne N, Torchia G, Muraca MG, Puccio G, Di Lorenzo R, Piccininni M, Tedde A, Maletta RG, Sorbi S, Bruni AC.

Neurobiol Aging. 2017 Aug;56:213.e7-213.e12. doi: 10.1016/j.neurobiolaging.2017.04.017. Epub 2017 Apr 27.

Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P.

J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309.

Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index

Lee C, Lee K, Yu H, Ryu SH, Moon SW, Han C, Lee JY, Lee YM, Kim SG, Kim KW, Lee DW, Kim SY, Lee SY, Bae JN, Jung YE, Kim JL, Kim BS, Shin IS, Kim YH, Kim BJ, Kang HS, Myung W, Carroll BJ, Kim DK.

J Clin Psychopharmacol. 2017 Aug;37(4):401-404. doi: 10.1097/JCP.0000000000000726.

Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body

Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T.

Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.

Cholinergic symptoms and QTc prolongation following donepezil overdose

Pourmand A, Shay C, Redha W, Aalam A, Mazer-Amirshahi M.

Am J Emerg Med. 2017 Sep;35(9):1386.e1-1386.e3. doi: 10.1016/j.ajem.2017.06.044. Epub 2017 Jun 22.

Alzheimer's Disease: Dawn of a New Era?

Amirrad F, Bousoik E, Shamloo K, Al-Shiyab H, Nguyen VV, Montazeri Aliabadi H.

J Pharm Pharm Sci. 2017;20(0):184-225. doi: 10.18433/J3VS8P.

The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial

Rijpma A, van der Graaf M, Lansbergen MM, Meulenbroek O, Cetinyurek-Yavuz A, Sijben JW, Heerschap A, Olde Rikkert MGM.

Alzheimers Res Ther. 2017 Jul 26;9(1):51. doi: 10.1186/s13195-017-0286-2.

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial

Park KW, Kim EJ, Han HJ, Shim YS, Kwon JC, Ku BD, Park KH, Yi HA, Kim KK, Yang DW, Lee HW, Kang H, Kwon OD, Kim S, Lee JH, Chung EJ, Park SW, Park MY, Yoon B, Kim BC, Seo SW, Choi SH.

PLoS One. 2017 Aug 7;12(8):e0182123. doi: 10.1371/journal.pone.0182123. eCollection 2017.

Location of white matter changes and response to donepezil in patients with Alzheimer's disease: A retrospective and observational study

Wu MN, Kao YH, Chou PS, Lin TC, Kao LL, Yang YH.

Geriatr Gerontol Int. 2018 Jan;18(1):123-129. doi: 10.1111/ggi.13153. Epub 2017 Aug 29.

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years

Wattmo C, Wallin ÅK.

Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2.

Changes in brain amyloid-β accumulation after donepezil administration

Ishibashi K, Miura Y, Wagatsuma K, Ishiwata K, Ishii K.

J Clin Neurosci. 2017 Nov;45:328-329. doi: 10.1016/j.jocn.2017.08.025. Epub 2017 Aug 31.

Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease

Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A.

Br J Pharmacol. 2017 Dec;174(23):4224-4232. doi: 10.1111/bph.14030. Epub 2017 Oct 29.

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease

Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Lehéricy S, Teipel S, Dubois B, Hampel H; Hippocampus Study Group.

Sci Rep. 2017 Sep 15;7(1):11706. doi: 10.1038/s41598-017-09780-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias